Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study-Reference-Cited by-同舟云学术

Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study

Published:2024-09-03 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Nakazawa Nobuhiro,Sohda Makoto,Hosoi Nobuhiro,Watanabe Takayoshi,Kumakura Yuji,Yamashita Toshiki,Tanaka Naritaka,Saito Kana,Kimura Akiharu,Kasuga Kengo,Nakazato Kenji,Yoshinari Daisuke,Shimizu Hisashi,Ubukata Yasunari,Hosaka Hisashi,Sano Akihiko,Sakai Makoto,Ogawa Hiroomi,Shirabe Ken,Saeki Hiroshi

Funder

JSPS KAKENHI

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-16161-4.pdf

Reference29 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalmedicine. 2022;47:101404.

3. Obama K, Kim YM, Kang DR, et al. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. 2018;21:285–95.

4. Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.

5. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.